Tarek Sahmoud
Plus aucun poste en cours
Profil
Tarek Sahmoud served as the Chief Medical Officer at Humanigen, Inc., Vice President at Novartis Corp., Chief Medical Officer at H3 Biomedicine, Inc., and Chief Medical Officer at Context Therapeutics, Inc. He obtained his undergraduate degree from KasrAlAiny School of Medicine in 1985 and his doctorate degree from Bordeaux Segalen University in 1995.
Anciens postes connus de Tarek Sahmoud
| Sociétés | Poste | Fin |
|---|---|---|
| CONTEXT THERAPEUTICS INC. | Directeur Technique/Scientifique/R&D | 31/12/2023 |
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Directeur Technique/Scientifique/R&D | 01/07/2017 |
Novartis Corp.
 Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
| HUMANIGEN, INC. | Directeur Technique/Scientifique/R&D | - |
Formation de Tarek Sahmoud
| KasrAlAiny School of Medicine | Undergraduate Degree |
| Bordeaux Segalen University | Doctorate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| HUMANIGEN, INC. | Health Technology |
| CONTEXT THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Health Technology |
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |